首页ANTH • OTCMKTS
add
Anthera Pharmaceuticals Inc
市场资讯
财务信息
损益表
收入
净收入
(USD) | 2017info | 年同比变化 |
---|---|---|
收入 | — | — |
经营支出 | 793.80万 | -28.30% |
净收入 | -2687.40万 | 51.60% |
净利润率 | — | — |
每股收益 | -3.80 | 70.53% |
息税折旧摊销前利润 | -3615.10万 | 36.48% |
有效税率 | — | — |
资产负债表
总资产
负债总额
(USD) | 2017info | 年同比变化 |
---|---|---|
现金及短期投资 | 219.60万 | -89.46% |
总资产 | 367.30万 | -84.35% |
负债总额 | 916.80万 | -13.70% |
权益总额 | -549.50万 | — |
发行在外的股份 | 2339.75万 | — |
市净率 | -0.00 | — |
资产回报率 | -167.77% | — |
资本回报率 | -619.42% | — |
现金流
现金净变动
(USD) | 2017info | 年同比变化 |
---|---|---|
净收入 | -2687.40万 | 51.60% |
来自运营的现金 | -3690.00万 | 24.57% |
投资现金 | — | — |
融资现金 | 1825.30万 | -22.58% |
现金净变动 | -1864.70万 | 28.58% |
自由现金流 | -2315.30万 | 18.17% |
简介
Anthera Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase, Anthera's leading drug candidate which is being developed for exocrine pancreatic insufficiency is currently in Phase 3 clinical trials, and A-623 for the treatment of IgA nephropathy is currently in Phase 2 clinical trial. Wikipedia
成立时间
2004
员工数量
21